The distinction between ALK- ALCL and PTCL-NOS with large cells and CD30 expression (CD30+ PTCL-NOS, approximately 10% of cases) is not only challenging but is also prone to subjectivity. This evidence concerns the gene ALK and anaplastic large cell lymphoma.